Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Major Breakthrough in the Fight against Antibiotic Resistance

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
'Resistance breaker’ compounds have been described as the most important innovation in the discovery of new antibiotics since Alexander Fleming’s original breakthrough.

Announcing the discovery as it inks its first licensing deal with Indian pharma giant Cadila Pharmaceuticals, Helperby Therapeutics' Chief Scientific Officer Professor Anthony Coates said “The emergence and spread of drug-resistant pathogens has accelerated whilst the pipeline for new anti-microbial drugs has all but run dry - this exciting and timely partnership with Cadila offers us all hope.”

The announcement comes as the World Health Organisation’s Director General Margaret Chan warns that a post-antibiotic era means, in effect, an end to modern medicine as we know it noting “Things as common as strep throat or a child’s scratched knee could once again kill.”

Helperby, a spin-out of the UK’s University of London St George’s, has been working for the past 12 years on ways to tackle antibiotic resistance and has discovered a new series of potent, fast-acting drugs which rescue old antibiotics. Instead of targeting multiplying bacteria, the research team focused on non-multiplying, dormant bacteria. Developing antibiotics that specifically target these root-like bacteria has never been done before - in fact conventional methods of screening have consistently missed these promising candidate drugs.

The lead compound, HT61, has proven effective at phase II where, combined with an existing antibiotic  it boosted the effect of the old antibiotic.  HT61 depolarizes the bacterial cell membrane boosting the anti-Staphylococcal effect of an old antibiotic for the decolonization of the nose prior to hospitalisation. This demonstrated that it is feasible to boost the effect of old antibiotics in humans – in essence a rejuvenated range of existing antibiotics. HT61 also renders a number of old antibiotics active against highly resistant bacteria- hence the name Antibiotic Resistance Breaker.

Cadila will take the compound through phase III, approvals and into commercialisation.  Helperby will supply Cadila with Antibiotic Resistance Breakers whilst Cadila will develop the combinations with old antibiotics. One of the largest privately held pharmaceutical organisations in India Cadila was the first Indian company to receive Investigational New Drug approval by the stringent Food and Drug Administration USA.  It is now actively considering a presence in the UK with a corresponding programme for UK microbiologists as part of the collaboration. The licensing agreement will allow Cadila Pharmaceuticals to bring the first product to market in around 18months.

Travelling with the UK’s Trade Delegation to India led by Prime Minister David Cameron, the deal value was undisclosed but could contribute to Helperby scaling up in the UK to a potential £500m operation, creating between 500-1000 by 2019.

Prime Minister Cameron said “The life sciences industry is the jewel in the crown for the UK economy, consistently growing and achieving new breakthroughs. Today’s deal between Helperby and Cadila Pharmaceuticals on antibiotic resistance research is another great example of UK-India collaboration helping both our countries to succeed in the global race. And it’s not just a step forward for medical research it also has the potential to create up to 1,000 highly skilled jobs in the UK by 2019.” 

Cadila’s Chairman and Managing Director Dr. Rajiv I Modi added “The Founder Chairman of our company, Shri IA Modi, believed in providing affordable medicines for the masses through innovative and cutting-edge research & development. This discovery will open new avenues against resistant organisms and is very timely in view of global concerns about rapidly growing bacterial resistance against current antibiotics. Cadila Pharmaceutical’s collaboration with Helperby can help the mankind win the battle against the microbes and hopefully save millions of lives in coming years.”

There has been a profound lack of appetite for antimicrobial drug development over the past two decades in favour of more lucrative areas such as orphans or long term condition therapeutics. As far back as 2006 the Antimicrobial Availability Task Force of the Infectious Diseases Society of America expressed concern at the decreasing investment in antimicrobial research and development and launched a Bad Bugs Need Drugs campaign. In spite of this the pipeline remains stagnant with no real rising stars likely to appear in the near future.

In contrast, Helperby has 300 small molecules and seven further programmes which are all at the preclinical stage, targeted at systemic and topical infection (Gram-positive and Gram-negative) indicated for a range of conditions including UTI, GUI, CF, skin and mucosal bacterial and fungal infections, eye and ear infections. With 49 patent applications in place the company is looking for further collaborative partners to fast-track these vital drugs to market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!